We Can Medicines (6929) 주식 개요는 대만에서 드럭스토어 체인을 운영하고 있습니다. 자세히 보기6929 펀더멘털 분석스노우플레이크 점수가치 평가4/6미래 성장0/6과거 실적0/6재무 건전성4/6배당0/6강점공정 가치 추정치보다 낮은 82.3% 에서 거래위험 분석지난 5년간 매년 수익이 82.2% 감소했습니다.의미 있는 시가총액이 없습니다(NT$976M)모든 위험 점검 보기6929 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueNT$Current PriceNT$21.659.6% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-70m3b2016201920222025202620282031Revenue NT$3.2bEarnings NT$96.9mAdvancedSet Fair ValueView all narrativesWe Can Medicines Co., Ltd. 경쟁사MedFirst Healthcare ServicesSymbol: TPEX:4175Market cap: NT$2.3bNorbel BabySymbol: TPEX:6844Market cap: NT$2.4bMARX BiotechSymbol: TPEX:7731Market cap: NT$3.1bGreat Tree PharmacySymbol: TPEX:6469Market cap: NT$10.7b가격 이력 및 성과We Can Medicines 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가NT$21.6552주 최고가NT$36.6052주 최저가NT$21.40베타-0.501개월 변동-20.11%3개월 변동-32.24%1년 변동-36.97%3년 변동-87.07%5년 변동n/aIPO 이후 변동-52.93%최근 뉴스 및 업데이트Reported Earnings • May 11First quarter 2026 earnings released: NT$0.21 loss per share (vs NT$0.28 loss in 1Q 2025)First quarter 2026 results: NT$0.21 loss per share (improved from NT$0.28 loss in 1Q 2025). Revenue: NT$796.9m (flat on 1Q 2025). Net loss: NT$9.61m (loss narrowed 23% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 11Full year 2025 earnings released: NT$1.63 loss per share (vs NT$1.09 loss in FY 2024)Full year 2025 results: NT$1.63 loss per share (further deteriorated from NT$1.09 loss in FY 2024). Revenue: NT$3.22b (down 1.4% from FY 2024). Net loss: NT$73.2m (loss widened 55% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.공시 • Feb 24We Can Medicines Co., Ltd., Annual General Meeting, May 29, 2026We Can Medicines Co., Ltd., Annual General Meeting, May 29, 2026. Location: no,335, jui kuang rd., neihu district, taipei city TaiwanReported Earnings • Nov 08Third quarter 2025 earnings released: NT$0.58 loss per share (vs NT$0.47 loss in 3Q 2024)Third quarter 2025 results: NT$0.58 loss per share (further deteriorated from NT$0.47 loss in 3Q 2024). Revenue: NT$789.5m (down 2.8% from 3Q 2024). Net loss: NT$26.2m (loss widened 26% from 3Q 2024).Reported Earnings • Aug 09Second quarter 2025 earnings released: NT$0.15 loss per share (vs NT$0.078 loss in 2Q 2024)Second quarter 2025 results: NT$0.15 loss per share (further deteriorated from NT$0.078 loss in 2Q 2024). Revenue: NT$816.8m (flat on 2Q 2024). Net loss: NT$6.66m (loss widened 102% from 2Q 2024).Reported Earnings • May 14First quarter 2025 earnings released: NT$0.28 loss per share (vs NT$0.27 profit in 1Q 2024)First quarter 2025 results: NT$0.28 loss per share (down from NT$0.27 profit in 1Q 2024). Revenue: NT$797.9m (down 2.5% from 1Q 2024). Net loss: NT$12.4m (down 215% from profit in 1Q 2024).더 많은 업데이트 보기Recent updatesReported Earnings • May 11First quarter 2026 earnings released: NT$0.21 loss per share (vs NT$0.28 loss in 1Q 2025)First quarter 2026 results: NT$0.21 loss per share (improved from NT$0.28 loss in 1Q 2025). Revenue: NT$796.9m (flat on 1Q 2025). Net loss: NT$9.61m (loss narrowed 23% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 11Full year 2025 earnings released: NT$1.63 loss per share (vs NT$1.09 loss in FY 2024)Full year 2025 results: NT$1.63 loss per share (further deteriorated from NT$1.09 loss in FY 2024). Revenue: NT$3.22b (down 1.4% from FY 2024). Net loss: NT$73.2m (loss widened 55% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.공시 • Feb 24We Can Medicines Co., Ltd., Annual General Meeting, May 29, 2026We Can Medicines Co., Ltd., Annual General Meeting, May 29, 2026. Location: no,335, jui kuang rd., neihu district, taipei city TaiwanReported Earnings • Nov 08Third quarter 2025 earnings released: NT$0.58 loss per share (vs NT$0.47 loss in 3Q 2024)Third quarter 2025 results: NT$0.58 loss per share (further deteriorated from NT$0.47 loss in 3Q 2024). Revenue: NT$789.5m (down 2.8% from 3Q 2024). Net loss: NT$26.2m (loss widened 26% from 3Q 2024).Reported Earnings • Aug 09Second quarter 2025 earnings released: NT$0.15 loss per share (vs NT$0.078 loss in 2Q 2024)Second quarter 2025 results: NT$0.15 loss per share (further deteriorated from NT$0.078 loss in 2Q 2024). Revenue: NT$816.8m (flat on 2Q 2024). Net loss: NT$6.66m (loss widened 102% from 2Q 2024).Reported Earnings • May 14First quarter 2025 earnings released: NT$0.28 loss per share (vs NT$0.27 profit in 1Q 2024)First quarter 2025 results: NT$0.28 loss per share (down from NT$0.27 profit in 1Q 2024). Revenue: NT$797.9m (down 2.5% from 1Q 2024). Net loss: NT$12.4m (down 215% from profit in 1Q 2024).Reported Earnings • Mar 15Full year 2024 earnings released: NT$1.09 loss per share (vs NT$0.37 profit in FY 2023)Full year 2024 results: NT$1.09 loss per share (down from NT$0.37 profit in FY 2023). Revenue: NT$3.27b (up 4.7% from FY 2023). Net loss: NT$47.2m (down 419% from profit in FY 2023).공시 • Feb 27We Can Medicines Co., Ltd., Annual General Meeting, Jun 11, 2025We Can Medicines Co., Ltd., Annual General Meeting, Jun 11, 2025. Location: 2 floor no,12, chou tzu st., neihu district, taipei city TaiwanReported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: NT$812.6m (up 4.9% from 3Q 2023). Net loss: NT$20.9m (loss widened 419% from 3Q 2023).Reported Earnings • Aug 17Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: NT$0.08 loss per share (improved from NT$0.16 loss in 2Q 2023). Revenue: NT$823.9m (up 7.7% from 2Q 2023). Net loss: NT$3.30m (loss narrowed 48% from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.27 (vs NT$0.16 in 1Q 2023)First quarter 2024 results: EPS: NT$0.27 (up from NT$0.16 in 1Q 2023). Revenue: NT$818.1m (up 6.5% from 1Q 2023). Net income: NT$10.8m (up 67% from 1Q 2023). Profit margin: 1.3% (up from 0.8% in 1Q 2023).New Risk • Apr 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 5.4% over the past year. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (NT$3.19b market cap, or US$97.8m).New Risk • Mar 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.20b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Revenue has declined by 5.4% over the past year. Minor Risks Profit margins are more than 30% lower than last year (0.5% net profit margin). Market cap is less than US$100m (NT$3.20b market cap, or US$99.9m).공시 • Mar 16We Can Medicines Co., Ltd., Annual General Meeting, May 27, 2024We Can Medicines Co., Ltd., Annual General Meeting, May 27, 2024.Reported Earnings • Mar 05Full year 2023 earnings released: EPS: NT$0.37 (vs NT$2.50 in FY 2022)Full year 2023 results: EPS: NT$0.37 (down from NT$2.50 in FY 2022). Revenue: NT$3.12b (down 5.4% from FY 2022). Net income: NT$14.8m (down 85% from FY 2022). Profit margin: 0.5% (down from 3.0% in FY 2022). The decrease in margin was driven by lower revenue.New Risk • Jan 23New major risk - Revenue and earnings growthRevenue has declined by 2.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 2.9% over the past year. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.5% net profit margin).주주 수익률6929TW Consumer RetailingTW 시장7D-5.9%-2.2%5.7%1Y-37.0%-17.1%108.5%전체 주주 수익률 보기수익률 대 산업: 6929은 지난 1년 동안 -17.1%의 수익을 기록한 TW Consumer Retailing 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 6929은 지난 1년 동안 108.5%를 기록한 TW 시장보다 저조한 성과를 냈습니다.주가 변동성Is 6929's price volatile compared to industry and market?6929 volatility6929 Average Weekly Movement5.2%Consumer Retailing Industry Average Movement3.1%Market Average Movement6.2%10% most volatile stocks in TW Market12.3%10% least volatile stocks in TW Market2.5%안정적인 주가: 6929는 지난 3개월 동안 TW 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 6929의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트19721,020De-Lan Wenwww.yourchance.com.tw는 대만에서 드럭스토어 체인을 운영하고 있습니다. 이 회사는 의약품, 건강식품, 산모 및 영유아 제품, 뷰티 케어 제품 및 의료 장비를 제공합니다. 바이탈플러스와 삿포로 브랜드로 소매점과 온라인을 통해 제품을 판매합니다.더 보기We Can Medicines Co., Ltd. 기초 지표 요약We Can Medicines의 순이익과 매출은 시가총액과 어떻게 비교됩니까?6929 기초 통계시가총액NT$975.72m순이익 (TTM)-NT$70.40m매출 (TTM)NT$3.22b0.3x주가매출비율(P/S)-13.9x주가수익비율(P/E)6929는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표6929 손익계산서 (TTM)매출NT$3.22b매출원가NT$2.16b총이익NT$1.06b기타 비용NT$1.13b순이익-NT$70.40m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)-1.56총이익률33.00%순이익률-2.19%부채/자본 비율17.2%6929의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/29 13:57종가2026/05/29 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스We Can Medicines Co., Ltd.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hsiu Chi LinMasterlink Securities Investment Advisory
Reported Earnings • May 11First quarter 2026 earnings released: NT$0.21 loss per share (vs NT$0.28 loss in 1Q 2025)First quarter 2026 results: NT$0.21 loss per share (improved from NT$0.28 loss in 1Q 2025). Revenue: NT$796.9m (flat on 1Q 2025). Net loss: NT$9.61m (loss narrowed 23% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 11Full year 2025 earnings released: NT$1.63 loss per share (vs NT$1.09 loss in FY 2024)Full year 2025 results: NT$1.63 loss per share (further deteriorated from NT$1.09 loss in FY 2024). Revenue: NT$3.22b (down 1.4% from FY 2024). Net loss: NT$73.2m (loss widened 55% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
공시 • Feb 24We Can Medicines Co., Ltd., Annual General Meeting, May 29, 2026We Can Medicines Co., Ltd., Annual General Meeting, May 29, 2026. Location: no,335, jui kuang rd., neihu district, taipei city Taiwan
Reported Earnings • Nov 08Third quarter 2025 earnings released: NT$0.58 loss per share (vs NT$0.47 loss in 3Q 2024)Third quarter 2025 results: NT$0.58 loss per share (further deteriorated from NT$0.47 loss in 3Q 2024). Revenue: NT$789.5m (down 2.8% from 3Q 2024). Net loss: NT$26.2m (loss widened 26% from 3Q 2024).
Reported Earnings • Aug 09Second quarter 2025 earnings released: NT$0.15 loss per share (vs NT$0.078 loss in 2Q 2024)Second quarter 2025 results: NT$0.15 loss per share (further deteriorated from NT$0.078 loss in 2Q 2024). Revenue: NT$816.8m (flat on 2Q 2024). Net loss: NT$6.66m (loss widened 102% from 2Q 2024).
Reported Earnings • May 14First quarter 2025 earnings released: NT$0.28 loss per share (vs NT$0.27 profit in 1Q 2024)First quarter 2025 results: NT$0.28 loss per share (down from NT$0.27 profit in 1Q 2024). Revenue: NT$797.9m (down 2.5% from 1Q 2024). Net loss: NT$12.4m (down 215% from profit in 1Q 2024).
Reported Earnings • May 11First quarter 2026 earnings released: NT$0.21 loss per share (vs NT$0.28 loss in 1Q 2025)First quarter 2026 results: NT$0.21 loss per share (improved from NT$0.28 loss in 1Q 2025). Revenue: NT$796.9m (flat on 1Q 2025). Net loss: NT$9.61m (loss narrowed 23% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 11Full year 2025 earnings released: NT$1.63 loss per share (vs NT$1.09 loss in FY 2024)Full year 2025 results: NT$1.63 loss per share (further deteriorated from NT$1.09 loss in FY 2024). Revenue: NT$3.22b (down 1.4% from FY 2024). Net loss: NT$73.2m (loss widened 55% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
공시 • Feb 24We Can Medicines Co., Ltd., Annual General Meeting, May 29, 2026We Can Medicines Co., Ltd., Annual General Meeting, May 29, 2026. Location: no,335, jui kuang rd., neihu district, taipei city Taiwan
Reported Earnings • Nov 08Third quarter 2025 earnings released: NT$0.58 loss per share (vs NT$0.47 loss in 3Q 2024)Third quarter 2025 results: NT$0.58 loss per share (further deteriorated from NT$0.47 loss in 3Q 2024). Revenue: NT$789.5m (down 2.8% from 3Q 2024). Net loss: NT$26.2m (loss widened 26% from 3Q 2024).
Reported Earnings • Aug 09Second quarter 2025 earnings released: NT$0.15 loss per share (vs NT$0.078 loss in 2Q 2024)Second quarter 2025 results: NT$0.15 loss per share (further deteriorated from NT$0.078 loss in 2Q 2024). Revenue: NT$816.8m (flat on 2Q 2024). Net loss: NT$6.66m (loss widened 102% from 2Q 2024).
Reported Earnings • May 14First quarter 2025 earnings released: NT$0.28 loss per share (vs NT$0.27 profit in 1Q 2024)First quarter 2025 results: NT$0.28 loss per share (down from NT$0.27 profit in 1Q 2024). Revenue: NT$797.9m (down 2.5% from 1Q 2024). Net loss: NT$12.4m (down 215% from profit in 1Q 2024).
Reported Earnings • Mar 15Full year 2024 earnings released: NT$1.09 loss per share (vs NT$0.37 profit in FY 2023)Full year 2024 results: NT$1.09 loss per share (down from NT$0.37 profit in FY 2023). Revenue: NT$3.27b (up 4.7% from FY 2023). Net loss: NT$47.2m (down 419% from profit in FY 2023).
공시 • Feb 27We Can Medicines Co., Ltd., Annual General Meeting, Jun 11, 2025We Can Medicines Co., Ltd., Annual General Meeting, Jun 11, 2025. Location: 2 floor no,12, chou tzu st., neihu district, taipei city Taiwan
Reported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: NT$812.6m (up 4.9% from 3Q 2023). Net loss: NT$20.9m (loss widened 419% from 3Q 2023).
Reported Earnings • Aug 17Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: NT$0.08 loss per share (improved from NT$0.16 loss in 2Q 2023). Revenue: NT$823.9m (up 7.7% from 2Q 2023). Net loss: NT$3.30m (loss narrowed 48% from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.27 (vs NT$0.16 in 1Q 2023)First quarter 2024 results: EPS: NT$0.27 (up from NT$0.16 in 1Q 2023). Revenue: NT$818.1m (up 6.5% from 1Q 2023). Net income: NT$10.8m (up 67% from 1Q 2023). Profit margin: 1.3% (up from 0.8% in 1Q 2023).
New Risk • Apr 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 5.4% over the past year. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (NT$3.19b market cap, or US$97.8m).
New Risk • Mar 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.20b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Revenue has declined by 5.4% over the past year. Minor Risks Profit margins are more than 30% lower than last year (0.5% net profit margin). Market cap is less than US$100m (NT$3.20b market cap, or US$99.9m).
공시 • Mar 16We Can Medicines Co., Ltd., Annual General Meeting, May 27, 2024We Can Medicines Co., Ltd., Annual General Meeting, May 27, 2024.
Reported Earnings • Mar 05Full year 2023 earnings released: EPS: NT$0.37 (vs NT$2.50 in FY 2022)Full year 2023 results: EPS: NT$0.37 (down from NT$2.50 in FY 2022). Revenue: NT$3.12b (down 5.4% from FY 2022). Net income: NT$14.8m (down 85% from FY 2022). Profit margin: 0.5% (down from 3.0% in FY 2022). The decrease in margin was driven by lower revenue.
New Risk • Jan 23New major risk - Revenue and earnings growthRevenue has declined by 2.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 2.9% over the past year. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.5% net profit margin).
